Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
PMID: 38436271